|View printer-friendly version|
|Organovo and Its Customers Present Data Supporting 3D Bioprinted Liver Tissues for Drug Toxicity Testing and Liver Fibrosis Modeling|
SAN DIEGO, March 10, 2016 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NYSE MKT:ONVO) (“Organovo”), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced five presentations at the Society of Toxicology’s (“SOT”) 55th Annual Meeting and ToxExpo, March 13–17, 2016, in New Orleans. These presentations demonstrate the broad applicability of Organovo’s exVive3DTM Human Liver Model for the assessment of drug safety and the detection of multiple clinically-relevant modes of liver injury, including steatosis and fibrosis. In addition, Organovo’s exhibitor-hosted session on March 15, at 9:00 a.m. Central Time (CT), in Room 212 will include oral presentations on recent advances using bioprinted 3D human liver tissues to assess drug-induced liver toxicity.
“Drug-induced liver injury remains a major cause of late-stage clinical failures and market withdrawal, often due to poor translation from preclinical animal studies to clinical outcomes,” said Dr. Sharon Presnell, chief technology officer and executive vice president of research & development, Organovo. “Organovo’s exVive3D human liver model replicates complex cell-cell interactions and key elements of native tissue architecture to enable the detection of multiple clinically-relevant modes of tissue injury, including necrosis, immune-mediated tissue damage, steatosis, and fibrosis. When a preclinical or clinical-stage asset presents a challenging safety or efficacy signal, exVive3D provides the unique resolving power of a controlled human tissue microenvironment to investigate mechanism and develop solutions.”
"Organovo’s exVive3D Human Liver Model provides an accurate, predictive and reproducible model of human liver biology for preclinical toxicity testing,” said Paul Gallant, general manager, Organovo. “At the SOT Annual Meeting, we and our pharmaceutical customers will be highlighting recent results that show our 3D bioprinted human liver tissue effectively models in vivo tissue composition and physiology.”
The presented data supports the use of the exVive3D Human Liver Model in:
The presentations are as follows:
Exhibitor-hosted Session: March 15, 9:00 a.m. - 10:00 a.m. CT, Room 212
Title: Advances in the Use of Bioprinted 3D Human Liver Tissues for the Assessment of
Poster Presentations: March 15, 9:30 a.m. - 12:45 p.m. CT, CC Exhibit Hall
Title: Functional Evaluation of Bioprinted Human Liver Organoid as a Liver Injury Model
Title: Modeling Drug Induced Hepatic Fibrosis In Vitro Using Three-Dimensional Liver
Title: Utilization of exVive3D Human Liver Tissues for the Evaluation of Valproic Acid
Title: Inflammatory Response of Kupffer Cells in 3D Bioprinted Human Liver Tissues
Late-breaking Poster Presentation: March 17, 9:30 a.m. - 12:45 p.m. CT, Great Hall A
Title: Monocrotaline Toxicity in 3D Bioprinted Human Liver Tissue
Exhibit Booth: March 14-16, 9:15 a.m. - 4:30 p.m. CT, Booth 1701, CC Exhibit Hall
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for use in medical research and therapeutic applications. The Company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo's 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. The Company recently launched its initial product of the planned exVive3D portfolio offering, the exVive3D Human Liver Tissue for use in toxicology and other preclinical drug testing. Additional products are in development, with the anticipated release of the exVive3D Human Kidney Tissue scheduled for the third quarter of calendar year 2016. The Company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous other media outlets. Organovo is changing the shape of medical research and practice. Learn more at www.organovo.com.
|Print Page | Email Page | RSS Feeds | Investor Contacts | Financial Tear Sheet|